Breaks Categories: News

TuesdayJul 22, 2025 9:10 am

BioMedNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Wins 2025 Innovation Award for Remote Cardiac Diagnostics

HeartBeam (NASDAQ: BEAT), a medical technology company advancing personalized cardiac care, has received the Innovation Award in Remote Cardiac Diagnostics from the 2025 Medical Device Network Excellence Awards. The honor recognizes HeartBeam’s FDA-cleared 3D ECG technology, which enables clinical-grade arrhythmia diagnostics in non-clinical settings via a compact, cable-free device. The synthesized 12-lead ECG software is under FDA review, with commercialization planned upon clearance. This award adds to HeartBeam’s growing list of accolades for its leadership in remote cardiac care. To view the full press release, visit https://ibn.fm/vEL8J About HeartBeam Inc. HeartBeam is a medical technology company dedicated to transforming cardiac…

Continue Reading

MondayJul 21, 2025 9:40 am

BioMedNewsBreaks – Lantern Pharma (NASDAQ: LTRN) Secures EU Patent for AI-Designed Cancer Drug LP-284

Lantern Pharma (NASDAQ: LTRN) announced the European Patent Office has issued a notice of allowance for a composition of matter patent covering LP-284, a clinical-stage drug candidate for relapsed or refractory non-Hodgkin's lymphoma. The patent, expected to grant with exclusivity through 2039, adds to existing IP in the U.S. and Japan and supports global commercialization efforts. LP-284, developed using Lantern’s RADR(R) AI platform, is in Phase 1 trials and holds Orphan Drug Designations for MCL and HGBL. The drug targets a $4 billion global market, and its rapid development timeline and cost efficiency bolster Lantern’s strategic partnership potential. To view…

Continue Reading

FridayJul 18, 2025 3:00 pm

BioMedNewsBreaks – NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Charts Dual-Path for NRX-100 

NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company developing innovative treatments for suicidal depression and PTSD, is accelerating its push toward regulatory approval of NRX-100, a preservative-free intravenous ketamine formulation. “The company recently filed an application under the newly created FDA Commissioner’s National Priority Voucher (‘CNPV’) program, which promises significantly shortened review timelines for drugs that meet urgent U.S. health priorities,” reads an article discussing NRx. “In parallel, the company has filed an Abbreviated New Drug Application (‘ANDA’) for NRX-100 with a request for priority review. The two pathways, CNPV and ANDA, are expected to complement one another. Should the…

Continue Reading

FridayJul 18, 2025 10:20 am

BioMedNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Sets Key Dates for 25% Preferred Stock Dividend

Nutriband (NASDAQ: NTRB) is reminding shareholders of its upcoming 25% preferred stock dividend. Shareholders of record as of July 25, 2025, will receive one preferred share for every four common shares held, with the dividend payable on August 5. Each preferred share will be convertible to one common share upon FDA approval of Nutriband’s AVERSA Fentanyl product. Unconverted preferred shares will be eligible for annual cash dividends from company profits at the discretion of the board. To view the full report, visit https://ibn.fm/wfve0 About Nutriband Inc. Nutriband is primarily engaged in the development of a portfolio of transdermal pharmaceutical products.…

Continue Reading

FridayJul 18, 2025 9:00 am

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces 1-for-12 Reverse Stock Split Effective July 22

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharma company focused on treating brain and CNS cancers, will implement a 1-for-12 reverse stock split effective July 22, 2025. Its common stock will continue trading under the symbol CNSP but with a new CUSIP number: 18978H508. Each 12 shares of common stock will convert into one, with proportional adjustments to warrants and equity awards. No fractional shares will be issued—holders will receive cash instead. The authorized share count will be reduced to 25 million, while par value remains $0.001. The move is designed to affect all shareholders uniformly. To view the full press release,…

Continue Reading

ThursdayJul 17, 2025 9:30 am

BioMedNewsBreaks — Fifty 1 Labs, Inc. (OTC: FITY) Announces Strategic Partnership and Intent to Acquire BioSpark AI to Advance Drug Repurposing 

Fifty 1 Labs (OTC: FITY) announced a strategic partnership and intent to acquire Vancouver-based BioSpark AI Technologies Inc., a leader in AI and large language model technologies. The alliance merges BioSpark’s literature mining platform with Fifty1’s predictive modeling to extract real-world clinical insights at scale—unlocking overlooked therapeutic patterns for drug repurposing. The partnership will support rapid identification of new formulations focused on performance health and preventative care, with proprietary delivery systems. The move reinforces Fifty1 AI Labs’ vision to lead in AI-powered functional medicine by integrating structured clinical data with advanced Bayesian inference and human-AI collaboration. To view the full…

Continue Reading

WednesdayJul 16, 2025 12:24 pm

BioMedNewsBreaks — Lantern Pharma (NASDAQ: LTRN) Taps IBN to Lead Corporate Communications Amid AI-Driven Oncology Pipeline Progress

  Lantern Pharma (NASDAQ: LTRN), a biotech company leveraging its RADR(R) AI platform to accelerate precision oncology drug development, has engaged IBN to lead its corporate communications strategy. With clinical programs targeting lung, brain, breast, and blood cancers—including three AI-guided candidates and a CNS-focused subsidiary—Lantern is advancing multiple FDA-designated therapies in active trials. The partnership with IBN aims to expand investor awareness as Lantern pursues key milestones across its data-driven, biomarker-informed pipeline. To view the full press release, visit https://ibn.fm/4jRwm About Lantern Pharma Lantern Pharma (NASDAQ: LTRN) is an AI company transforming the cost, pace, and timeline of oncology drug…

Continue Reading

TuesdayJul 15, 2025 2:30 pm

BioMedNewsBreaks – Zacks Research Releases Updated Report as Soligenix Inc. (NASDAQ: SNGX) Eyes Upcoming ‘Key Catalysts’

Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company targeting rare diseases, was spotlighted in a July 10 Zacks Small-Cap Research report that presented a favorable analysis, noting that the company is anticipating a number of key catalysts in the second half of 2025, including progress on its current phase 3 FLASH2 trial of HyBryte(TM) for the treatment of early-stage cutaneous T cell lymphoma (“CTCL”). According to the report, Soligenix is developing products to treat rare diseases within two business segments: Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics business segment currently has multiple products under development, and the report noted…

Continue Reading

TuesdayJul 15, 2025 11:20 am

BioMedNewsBreaks – Lantern Pharma (NASDAQ: LTRN) Launches AI Module to Accelerate Development of Targeted Cancer Combination Therapies

Lantern Pharma (NASDAQ: LTRN), an AI-driven oncology drug developer, announced the launch of a new AI-powered module within its RADR(R) platform to predict the efficacy of combination therapies involving DNA-damaging agents (DDAs) and DNA damage response inhibitors (DDRis). Backed by a peer-reviewed analysis of 221 clinical trials, the tool enables precise, biomarker-guided design of cancer treatment regimens, reducing development time and cost by up to one-third. The platform guided the design of Lantern’s FDA-cleared Phase 1B/2 trial in triple-negative breast cancer combining LP-184 and olaparib. Lantern is exploring licensing and commercialization opportunities to scale the system across oncology indications. To…

Continue Reading

FridayJul 11, 2025 9:00 am

BioMedNewsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) Featured in NetworkNewsWire Spotlight on Genetic Medicines 

Calidi Biotherapeutics (NYSE American: CLDI), a clinical-stage biotech innovator, announced its inclusion in an editorial by NetworkNewsWire titled “Breaking Through: Systemic Genetic Medicines for Hard-to-Treat Cancers.” The article highlights Calidi’s next-generation platform, which uses engineered viruses to deliver genetic therapies directly to primary and metastatic tumors. While oncology is the company's initial focus, it is also evaluating applications in autoimmune disorders, underscoring its broader therapeutic potential. The editorial emphasizes Calidi’s role in addressing the rising global cancer burden and advancing transformative treatment options.  To view the full press release, visit: https://ibn.fm/tRB9D About Calidi Biotherapeutics  Calidi Biotherapeutics is a clinical-stage immuno-oncology…

Continue Reading